title: [An assessment of the management of spasticity in Spain: the 5E Study].
abstract: BACKGROUND
  Although spasticity is a disabling complication of high incidence, there is a lack of either regional or national epidemiological studies in Spain evaluating its management.
  
  
  OBJECTIVE
  To evaluate the management of spasticity in Spain.
  
  
  METHODS
  An epidemiological, observational, multicenter, and retrospective study involving 49 rehabilitation services of public and private hospitals was designed.
  
  
  RESULTS
  Two hundred and thirty-five patients from 49 centers, with evidence of upper (UL) or lower limb (LL) spasticity with one valid baseline visit and at least one follow-up visit, were included. Among the patients included in the study 148 (62.9%) have post stroke spasticity; 79 (33.6%) have LL spasticity, 38 (16.1%) UL, and 118 (50.3%) in both. At baseline, Modified Ashworth Scale, goniometry, Visual Analog Scale for pain and Tardieu Scale had been performed in 164 (69.8%), 99 (42.1%), 85 (36.2%), and 26 (11.1%) patients, respectively. A 93.8% (IC 95%: 81.4-97.6%) of the centers accurately defined the treatment goals and 52% of the objectives were agreed with the patient. Botulinum A toxin was administered in 186 (79.1%) of patients; 49 (20.9%) patients were treated with oral antispastic medications and 93 (39.6%) were under physiotherapy treatment.
  
  
  CONCLUSIONS
  Most of the patients have post-stroke spasticity. Moreover, botulinum A toxin was the most commonly treatment applied to patients with spasticity. The results demonstrate that the management of spasticity varies significantly across the different centers participating in the study.
authors.affiliation: Hospital Mutua de Terrasa, 08221 Terrassa, Espana.
authors.forename: R
authors.initials: R
authors.lastname: Garreta-Figuera
authors.affiliation: Hospital Mutua de Terrassa, Terrassa, Espana.
authors.forename: A
authors.initials: A
authors.lastname: Torrequebrada-Gimenez
authors.forename: En Representacion Del Grupo de Estudio 5e
authors.initials: ER
authors.lastname: En Representacion Del Grupo de Estudio 5e
mesh_terms: D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D006801:Humans; D035002:Lower Extremity / Q000503:physiopathology*; D009128:Muscle Spasticity / Q000628:therapy*; D009465:Neuromuscular Agents / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D012189:Retrospective Studies; D013030:Spain; D020521:Stroke / Q000150:complications; D000071939:Stroke Rehabilitation; D016896:Treatment Outcome
chemical_list: D009465:Neuromuscular Agents; D010276:Parasympatholytics; D019274:Botulinum Toxins, Type A